Barclays analyst Luke Sergott double downgraded Syneos Health to Underweight from Overweight with a price target of $25, down from $30. The analyst sees a tale of two halves in 2023 for the contract research organizations, with biotech funding weak through the first half and "some relief" in the second half once the macro environment turns more positive. He upgraded Icon and double downgraded Syneos as part of his 2023 outlook.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SYNH:
- Syneos Health downgraded to Underweight from Overweight at Barclays
- Syneos Health Announces Partnership with Fosun Pharma USA to Launch Serplulimab
- Syneos Health partners with Fosun Pharma USA to launch serplulimab
- Syneos Health Dealmakers’ Intentions Survey Sees “Optimism” for M&A and Licensing Deals in 2023
- Syneos Health backs FY22 EPS view $4.69-$4.87, consensus $4.70
